Anthrax Infection Treatments
Find Anthrax Infection Treatments
Brand Name
Anthim
Generic Name
Obiltoxaximab
View Brand Information FDA approval date: March 18, 2016
Classification: Anthrax Protective Antigen-directed Antibody
Form: Solution
What is Anthim (Obiltoxaximab)?
ANTHIM ® is a monoclonal antibody directed against the protective antigen of Bacillus anthracis. It is indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment